44th Annual J.P. Morgan Healthcare Conference
Logotype for Rapid Micro Biosystems Inc

Rapid Micro Biosystems (RPID) 44th Annual J.P. Morgan Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Rapid Micro Biosystems Inc

44th Annual J.P. Morgan Healthcare Conference summary

15 Jan, 2026

Business overview and market context

  • Automates microbial quality control in pharmaceutical manufacturing, replacing manual Petri dish methods with the Growth Direct Platform.

  • Operates in about 20 countries, serving 75% of the global top 20 pharma companies and 86% of approved CAR-T manufacturers, excelling in biologics and cell/gene therapy.

  • 190 systems placed globally, with 155 validated for routine use and presence at over 100 customer manufacturing sites.

  • Recurring revenue forms a strong base, with over half of annual revenue from consumables and service contracts, and over 9 million consumables sold.

  • The platform is modality-agnostic, integrates with customer data systems, and supports applications like environmental monitoring, water testing, bioburden, and rapid sterility testing.

Financial performance and growth

  • Achieved $34 million in 2025 revenue, up 20% year-over-year, with $18 million in recurring revenue and 53% of total revenue.

  • Q4 revenue reached $11.3 million, a 37% increase year-over-year, with 16 systems placed and 3 validated.

  • 13 consecutive quarters of meeting or exceeding revenue guidance, with strong gross margin growth.

  • Reinforced balance sheet with a $45 million facility, ending 2025 with $38 million in cash.

  • Record multi-system order from an existing customer, expanding globally and adopting all core applications.

Strategic initiatives and partnerships

  • Land and expand strategy: initial system placements followed by network-wide expansion and application onboarding.

  • Innovation focus includes expanding platform capabilities and targeting adjacent markets like food, beverage, and medical devices.

  • Partnership with MilliporeSigma aims to drive growth, margin expansion, and access to new markets, with significant impact expected in 2026.

  • Commercial momentum supported by multi-system orders and expanding recurring revenue from consumables and services.

  • Annual Growth Direct Day event fosters customer engagement, with the 7th edition hosting over 25 companies and 100 attendees from the U.S., Europe, and Asia.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more